FDA slaps Im­prim­is­Rx with a warn­ing let­ter over spon­sored ar­ti­cles in med­ical jour­nals

Im­prim­is­Rx is in hot wa­ter with the FDA for false and mis­lead­ing claims about its com­pound­ed drug for post­op­er­a­tive eye pain called Pred-Moxi-Brom.

Spon­sored ar­ti­cles that ran in two oph­thal­mol­o­gy jour­nals last year crossed the line by po­si­tion­ing the com­pound’s com­po­nents as FDA-ap­proved while Im­prim­is us­es bulk drug sub­stances, the FDA says in its let­ter. The ti­tle of one of the spon­sored ar­ti­cles is “Pred-Moxi-Brom: The Whole Is Greater Than The Sum Of Its Parts.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.